ID

31876

Beschrijving

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00847886

Link

https://clinicaltrials.gov/show/NCT00847886

Trefwoorden

Versies (1)
  1. 06-10-18 06-10-18 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

6 oktober 2018

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Rheumatoid Arthritis NCT00847886

Engels

Eligibility Rheumatoid Arthritis NCT00847886

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
males and females ≥ 18 years old
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
must be willing to practice 2 adequate methods of contraception for the duration of the study
Beschrijving

Contraceptive methods Quantity Willing

Datatype

boolean

Alias
UMLS CUI [1,1]
C0700589
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0600109
rheumatoid arthritis present for at least 3 months; functional class i, ii, or iii as defined by acr criteria
Beschrijving

Rheumatoid Arthritis Functional Status Class Disease length

Datatype

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0598463
UMLS CUI [1,3]
C0456387
UMLS CUI [1,4]
C0872146
treatment with methotrexate (7.5 to 25 mg per week) for at least the last 3 months, and currently receiving stable dose methotrexate for at least one month prior to the start of the study
Beschrijving

Methotrexate U/week | Methotrexate Dose Stable

Datatype

boolean

Alias
UMLS CUI [1,1]
C0025677
UMLS CUI [1,2]
C0560588
UMLS CUI [2,1]
C0025677
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
ability to provide written informed consent
Beschrijving

Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
women who are pregnant or nursing
Beschrijving

Pregnancy | Breast Feeding

Datatype

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
history of other current inflammatory arthritis
Beschrijving

Arthritis Other

Datatype

boolean

Alias
UMLS CUI [1,1]
C0003864
UMLS CUI [1,2]
C0205394
history of opportunistic infection
Beschrijving

Opportunistic Infection

Datatype

boolean

Alias
UMLS CUI [1]
C0029118
history of recurrent infections or current infection 2 weeks prior to start of study
Beschrijving

Recurrent infections | Communicable Disease

Datatype

boolean

Alias
UMLS CUI [1]
C0239998
UMLS CUI [2]
C0009450
presence of significant, uncontrolled medical problems
Beschrijving

Medical Problem Uncontrolled

Datatype

boolean

Alias
UMLS CUI [1,1]
C1254481
UMLS CUI [1,2]
C0205318
treatment with any disease-modifying anti-rheumatoid drugs other than methotrexate within 4 weeks prior to start of study
Beschrijving

Antirheumatic Drugs, Disease-Modifying | Exception Methotrexate

Datatype

boolean

Alias
UMLS CUI [1]
C0242708
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0025677
use of chondroitin sulfate, glucosamine sulfate, minocycline, or matrix metalloproteinase inhibitors, h-2 blockers, proton pump inhibitors, or misoprostol within 4 weeks prior to study start
Beschrijving

Chondroitin Sulfates | Glucosamine Sulfate | Minocycline | Matrix Metalloproteinase Inhibitors | H2 blockers | Proton Pump Inhibitors | Misoprostol

Datatype

boolean

Alias
UMLS CUI [1]
C0008466
UMLS CUI [2]
C0017720
UMLS CUI [3]
C0026187
UMLS CUI [4]
C1513016
UMLS CUI [5]
C0019593
UMLS CUI [6]
C0358591
UMLS CUI [7]
C0085174
receipt of live vaccine within 8 weeks prior to study start
Beschrijving

Live vaccine

Datatype

boolean

Alias
UMLS CUI [1]
C0042211
rheumatoid arthritis, functional class iv as defined by acr criteria
Beschrijving

Rheumatoid Arthritis Functional Status Class

Datatype

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0598463
UMLS CUI [1,3]
C0456387
Terug naar het begin van de pagina

Similar models

Eligibility Rheumatoid Arthritis NCT00847886

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
males and females ≥ 18 years old
boolean
C0001779 (UMLS CUI [1])
Contraceptive methods Quantity Willing
Item
must be willing to practice 2 adequate methods of contraception for the duration of the study
boolean
C0700589 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
Rheumatoid Arthritis Functional Status Class Disease length
Item
rheumatoid arthritis present for at least 3 months; functional class i, ii, or iii as defined by acr criteria
boolean
C0003873 (UMLS CUI [1,1])
C0598463 (UMLS CUI [1,2])
C0456387 (UMLS CUI [1,3])
C0872146 (UMLS CUI [1,4])
Methotrexate U/week | Methotrexate Dose Stable
Item
treatment with methotrexate (7.5 to 25 mg per week) for at least the last 3 months, and currently receiving stable dose methotrexate for at least one month prior to the start of the study
boolean
C0025677 (UMLS CUI [1,1])
C0560588 (UMLS CUI [1,2])
C0025677 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Informed Consent
Item
ability to provide written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
women who are pregnant or nursing
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Arthritis Other
Item
history of other current inflammatory arthritis
boolean
C0003864 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
Opportunistic Infection
Item
history of opportunistic infection
boolean
C0029118 (UMLS CUI [1])
Recurrent infections | Communicable Disease
Item
history of recurrent infections or current infection 2 weeks prior to start of study
boolean
C0239998 (UMLS CUI [1])
C0009450 (UMLS CUI [2])
Medical Problem Uncontrolled
Item
presence of significant, uncontrolled medical problems
boolean
C1254481 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Antirheumatic Drugs, Disease-Modifying | Exception Methotrexate
Item
treatment with any disease-modifying anti-rheumatoid drugs other than methotrexate within 4 weeks prior to start of study
boolean
C0242708 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0025677 (UMLS CUI [2,2])
Chondroitin Sulfates | Glucosamine Sulfate | Minocycline | Matrix Metalloproteinase Inhibitors | H2 blockers | Proton Pump Inhibitors | Misoprostol
Item
use of chondroitin sulfate, glucosamine sulfate, minocycline, or matrix metalloproteinase inhibitors, h-2 blockers, proton pump inhibitors, or misoprostol within 4 weeks prior to study start
boolean
C0008466 (UMLS CUI [1])
C0017720 (UMLS CUI [2])
C0026187 (UMLS CUI [3])
C1513016 (UMLS CUI [4])
C0019593 (UMLS CUI [5])
C0358591 (UMLS CUI [6])
C0085174 (UMLS CUI [7])
Live vaccine
Item
receipt of live vaccine within 8 weeks prior to study start
boolean
C0042211 (UMLS CUI [1])
Rheumatoid Arthritis Functional Status Class
Item
rheumatoid arthritis, functional class iv as defined by acr criteria
boolean
C0003873 (UMLS CUI [1,1])
C0598463 (UMLS CUI [1,2])
C0456387 (UMLS CUI [1,3])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial